An Unrelated Monoclonal Antibody Neutralizes Human Immunodeficiency Virus Type 1 by Binding to an Artificial Epitope Engineered in a Functionally Neutral Region of the Viral Envelope Glycoproteins

ABSTRACT Neutralizing antibodies often recognize regions of viral envelope glycoproteins that play a role in receptor binding or other aspects of virus entry. To address whether this is a necessary feature of a neutralizing antibody, we identified the V4 region of the gp120 envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1) as a sequence that is tolerant of drastic change and thus appears to play a negligible role in envelope glycoprotein function. An artificial epitope tag was inserted into the V4 region without a significant effect on virus entry or neutralization by antibodies that recognize HIV-1 envelope glycoprotein sequences. An antibody directed against the artificial epitope tag was able to neutralize the modified, but not the wild-type, HIV-1. Thus, the specific target of a neutralizing antibody need not contribute functionally to the process of virus entry.

[1]  A. Trkola,et al.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG , 1995, Journal of virology.

[2]  Gregory J Babcock,et al.  Ligand-independent Dimerization of CXCR4, a Principal HIV-1 Coreceptor* , 2003, The Journal of Biological Chemistry.

[3]  J. Sodroski,et al.  Oligomeric Modeling and Electrostatic Analysis of the gp120 Envelope Glycoprotein of Human Immunodeficiency Virus , 2000, Journal of Virology.

[4]  Q. Sattentau,et al.  Neutralization of Human Immunodeficiency Virus Type 1 by Antibody to gp120 Is Determined Primarily by Occupancy of Sites on the Virion Irrespective of Epitope Specificity , 1998, Journal of Virology.

[5]  M. Greenberg,et al.  Evolution of the Human Immunodeficiency Virus Type 1 Envelope during Infection Reveals Molecular Corollaries of Specificity for Coreceptor Utilization and AIDS Pathogenesis , 2000, Journal of Virology.

[6]  S. Zolla-Pazner,et al.  Conserved and Exposed Epitopes on Intact, Native, Primary Human Immunodeficiency Virus Type 1 Virions of Group M , 2000, Journal of Virology.

[7]  R. Daniels,et al.  Short Communication: env Gene Sequences of Primary HIV Type 1 Isolates of Subtypes B, C, D, E, and F Obtained from the World Health Organization Network for HIV Isolation and Characterization , 1996 .

[8]  C. Griscelli,et al.  Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes. , 1984, Science.

[9]  Deborah Fass,et al.  Core Structure of gp41 from the HIV Envelope Glycoprotein , 1997, Cell.

[10]  J. Kappes,et al.  Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes , 1991, Journal of virology.

[11]  Wayne C Koff,et al.  HIV vaccine design and the neutralizing antibody problem , 2004, Nature Immunology.

[12]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.

[13]  D. Chan,et al.  The Prefusogenic Intermediate of HIV-1 gp41 Contains Exposed C-peptide Regions* , 2003, The Journal of Biological Chemistry.

[14]  L. Stamatatos,et al.  Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication. , 1998, AIDS research and human retroviruses.

[15]  Hans Wolf,et al.  Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS , 1986, Cell.

[16]  John P. Moore,et al.  Nonneutralizing Antibodies to the CD4-Binding Site on the gp120 Subunit of Human Immunodeficiency Virus Type 1 Do Not Interfere with the Activity of a Neutralizing Antibody against the Same Site , 2003, Journal of Virology.

[17]  Ying Sun,et al.  The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates , 1996, Cell.

[18]  A. Plückthun,et al.  Identification of new tag sequences with differential and selective recognition properties for the anti-FLAG monoclonal antibodies M1, M2 and M5 , 2005, Molecular Diversity.

[19]  G. Shaw,et al.  Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions , 1987, Journal of virology.

[20]  D. Burton,et al.  Heterogeneity of Envelope Molecules Expressed on Primary Human Immunodeficiency Virus Type 1 Particles as Probed by the Binding of Neutralizing and Nonneutralizing Antibodies , 2003, Journal of Virology.

[21]  P S Kim,et al.  Mechanisms of viral membrane fusion and its inhibition. , 2001, Annual review of biochemistry.

[22]  C. Barbas,et al.  Determinants of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Activation by Soluble CD4 and Monoclonal Antibodies , 1998, Journal of Virology.

[23]  D. Ho,et al.  Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120 , 1992, Journal of virology.

[24]  J. Sodroski,et al.  Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. , 1987, Science.

[25]  Virginia Litwin,et al.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 , 1996, Nature.

[26]  R. F. Smith,et al.  Human Retroviruses and AIDS. A compilation and analysis of nucleic acid and amino acid sequences: I--II; III--V , 1993 .

[27]  Joseph Sodroski,et al.  Stoichiometry of Antibody Neutralization of Human Immunodeficiency Virus Type 1 , 2005, Journal of Virology.

[28]  S. Harrison,et al.  Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.

[29]  C. Weiss,et al.  Capture of an early fusion-active conformation of HIV-1 gp41 , 1998, Nature Structural Biology.

[30]  J. Sodroski,et al.  Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding , 1995, Journal of virology.

[31]  G Himmler,et al.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 , 1993, Journal of virology.

[32]  M. Martin,et al.  Identification of conserved and divergent domains within the envelope gene of the acquired immunodeficiency syndrome retrovirus. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Sodroski,et al.  Species-Specific, Postentry Barriers to Primate Immunodeficiency Virus Infection , 1999, Journal of Virology.

[34]  L. Cavacini,et al.  Native HIV type 1 virion surface structures: relationships between antibody binding and neutralization or lessons from the viral capture assay. , 2004, AIDS research and human retroviruses.

[35]  J. Sodroski,et al.  Loss of a Single N-Linked Glycan Allows CD4-Independent Human Immunodeficiency Virus Type 1 Infection by Altering the Position of the gp120 V1/V2 Variable Loops , 2001, Journal of Virology.

[36]  P. S. Kim,et al.  HIV Entry and Its Inhibition , 1998, Cell.

[37]  J. Rose,et al.  Prediction and Identification of a Permissive Epitope Insertion Site in the Vesicular Stomatitis Virus Glycoprotein , 2004, Journal of Virology.

[38]  Q. Sattentau,et al.  Mechanisms of virus neutralization by antibody. , 2001, Current topics in microbiology and immunology.

[39]  R. Doms,et al.  Relationships between CD4 Independence, Neutralization Sensitivity, and Exposure of a CD4-Induced Epitope in a Human Immunodeficiency Virus Type 1 Envelope Protein , 2001, Journal of Virology.

[40]  C. Kuiken,et al.  HIV sequence databases. , 2003, AIDS reviews.

[41]  J. Sodroski,et al.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.

[42]  Nga Nguyen,et al.  Peptides Trap the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Fusion Intermediate at Two Sites , 2003, Journal of Virology.

[43]  William C. Olson,et al.  CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 , 1996, Nature.

[44]  J. Sodroski,et al.  Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[45]  W A Hendrickson,et al.  Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. , 2000, Structure.

[46]  Stephen C. Peiper,et al.  Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.

[47]  E. Fenyö,et al.  Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization. , 1997, Virology.

[48]  J. Sodroski,et al.  Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120. , 2000, AIDS research and human retroviruses.

[49]  Gilcher Ro.  Human retroviruses and AIDS. , 1988 .

[50]  A. Trkola,et al.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.

[51]  J. Sodroski,et al.  Role of the gp120 inner domain beta-sandwich in the interaction between the human immunodeficiency virus envelope glycoprotein subunits. , 2003, Virology.

[52]  Marc Parmentier,et al.  A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion Cofactors , 1996, Cell.

[53]  Christoph Grundner,et al.  Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1 , 2003, Journal of Virology.

[54]  N. Greenspan.  Affinity, complementarity, cooperativity, and specificity in antibody recognition. , 2001, Current topics in microbiology and immunology.

[55]  P. Sharp,et al.  Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: evidence for limited defectiveness and complementation , 1992, Journal of virology.

[56]  P. Sharp,et al.  Genetic variation of HIV type 1 in four World Health Organization-sponsored vaccine evaluation sites: generation of functional envelope (glycoprotein 160) clones representative of sequence subtypes A, B, C, and E. WHO Network for HIV Isolation and Characterization. , 1994, AIDS research and human retroviruses.

[57]  Joseph Sodroski,et al.  CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5 , 1996, Nature.

[58]  Ying Sun,et al.  A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. , 1998, Science.

[59]  C. Broder,et al.  CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1 , 1996, Science.

[60]  Luc Montagnier,et al.  T-lymphocyte T4 molecule behaves as the receptor for human retrovirus  LAV , 1984, Nature.

[61]  Q. Sattentau,et al.  Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding , 1993, Journal of virology.

[62]  A. Papavassiliou,et al.  The insertion of an anti-MHC I ScFv into the N-terminus of an ecotropic MLV glycoprotein does not alter its fusiogenic potential on murine cells. , 2002, Virus research.

[63]  J. Sodroski,et al.  Identification of Membrane Anchorage Domains of the HIV‐1 gp160 Envelope Glycoprotein Precursor , 1991, Journal of acquired immune deficiency syndromes.

[64]  J. Sodroski,et al.  Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions , 1993, Journal of virology.

[65]  J. Sodroski,et al.  The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry , 1996, Nature.

[66]  I. Weissman,et al.  Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus , 1988, Cell.

[67]  Reed J. Harris,et al.  Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. , 1990, The Journal of biological chemistry.

[68]  Bernhard Moser,et al.  The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1 , 1996, Nature.

[69]  Peter D. Kwong,et al.  The antigenic structure of the HIV gp120 envelope glycoprotein , 1998, Nature.

[70]  J. Sodroski,et al.  The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. , 1998, Science.

[71]  J. Manola,et al.  Membrane-Fusing Capacity of the Human Immunodeficiency Virus Envelope Proteins Determines the Efficiency of CD4+ T-Cell Depletion in Macaques Infected by a Simian-Human Immunodeficiency Virus , 2001, Journal of Virology.

[72]  Stephen C. Blacklow,et al.  A trimeric structural domain of the HIV-1 transmembrane glycoprotein , 1995, Nature Structural Biology.

[73]  J. Moore,et al.  Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1 , 1996, Journal of virology.

[74]  J. Sodroski,et al.  Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein , 1997, Journal of virology.

[75]  Brian T. Foley,et al.  Retrieval and on-the-fly alignment of sequence fragments from the HIV database , 2001, Bioinform..

[76]  M. Greaves,et al.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus , 1984, Nature.